Autologous RAK Cells (CICAMS/Ever Cell)

Primary objective: To evaluate the efficacy of intravenous infusion of autologous RAK cells or intravenous infusion of autologous RAK cells combined with TACE in preventing recurrence in patients with primary hepatocellular carcinoma who have undergone radical resection and are at high risk of recurrence. Secondary objective: To investigate the safety of intravenous infusion of autologous RAK cells or intravenous infusion of autologous RAK cells combined with TACE. Exploratory objective: Evaluation of immune effects, potential serum biomarkers, proteomics, and ctDNA analysis to explore the characteristics of patients at high risk of recurrence and/or analyze the potential advantage population of autologous RAK cell injection.

1. To evaluate the safety and tolerability of autologous RAK cell therapy in patients with metastatic renal cancer who cannot undergo surgical resection and have failed ≥1 line of systemic treatment, and to explore the maximum tolerated dose; 2. To recommend the infusion dose and regimen for subsequent clinical trials of autologous RAK cell infusion therapy. 3. To explore the immunological mechanism and effector principle of autologous RAK cells.